<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="lpi" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">lpi</book-part-id>
      <title-group>
        <title>Lysinuric Protein Intolerance</title>
        <alt-title alt-title-type="alt-title">Synonym: Cationic Aminoaciduria</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sebastio</surname>
            <given-names>Gianfranco</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="lpi.Tc.aff1"/>
          <email>sebastio@unina.it</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nunes</surname>
            <given-names>Virginia</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="lpi.Tc.aff2"/>
          <xref ref-type="aff" rid="lpi.Tc.aff3"/>
          <xref ref-type="aff" rid="lpi.Tc.aff4"/>
          <email>vnunes@ub.edu</email>
          <email>vnunes@idibell.cat</email>
        </contrib>
      </contrib-group>
      <aff id="lpi.Tc.aff1">Associate Professor of Pediatrics <break/>Department of Pediatrics <break/>Federico II University <break/>Naples, Italy</aff>
      <aff id="lpi.Tc.aff2">Professor of Genetics, Genetics Unit<break/>Physiological Sciences II<break/>Faculty of Medicine - Bellvitge Campus<break/>University of Barcelona</aff>
      <aff id="lpi.Tc.aff3">Senior Investigator, Molecular Genetics Laboratory<break/>Instituto de Investigaci&#x000f3;n Biom&#x000e9;dica de Bellvitge</aff>
      <aff id="lpi.Tc.aff4">Chief, Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Raras U730<break/>Barcelona, Spain</aff>
      <pub-history>
        <date date-type="created">
          <day>21</day>
          <month>12</month>
          <year>2006</year>
        </date>
        <date date-type="updated">
          <day>31</day>
          <month>5</month>
          <year>2011</year>
        </date>
        <date date-type="revised">
          <day>13</day>
          <month>10</month>
          <year>2011</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hnpcc" document-type="chapter">Lynch Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="lal-def" document-type="chapter">Lysosomal Acid Lipase Deficiency</related-object>
      <abstract id="lpi.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Lysinuric protein intolerance (LPI) typically presents after an infant is weaned; variable findings include recurrent vomiting and episodes of diarrhea, episodes of stupor and coma after a protein-rich meal, poor feeding, aversion to protein-rich food, failure to thrive, hepatosplenomegaly, and muscular hypotonia. Over time, findings include: poor growth; osteoporosis; involvement of the lungs (progressive interstitial changes; pulmonary alveolar proteinosis) and of kidneys (progressive glomerular and proximal tubular disease); hematologic abnormalities (normochromic or hypochromic anemia, leukopenia, thrombocytopenia, erythroblastophagocytosis at the bone marrow aspirate) and a clinical presentation resembling the hemophagocytic lymphohistiocytosis/macrophagic activation syndrome. Acute pancreatitis can also be seen.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Plasma ammonia concentration may be elevated after a protein-rich meal. Plasma concentrations of cationic amino acids (lysine, arginine, and ornithine) are usually below normal for age but may be within the normal range. Plasma concentrations of serine, glycine, citrulline, proline, alanine, and glutamine are increased. Urinary orotic acid excretion is frequently increased. Twenty-four-hour urinary excretion of cationic amino acids, especially lysine, is increased. Plasma concentrations of TBG, LDH, and ferritin are usually elevated. Hypertriglyceridemia and hypercholesterolemia are frequently observed. <italic toggle="yes">SLC7A7</italic> is the only gene in which pathogenic variants are currently known to cause LPI. Molecular genetic testing identifies two <italic toggle="yes">SLC7A7</italic> pathogenic variants in more than 95% of individuals with typical biochemical findings of LPI.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: In acute hyperammonemic crises: intravenous administration of arginine chloride and nitrogen scavenger drugs (sodium benzoate, sodium phenylacetate) to block ammonia production; reduction of excess nitrogen in the diet; providing energy as carbohydrates to reduce catabolism. Long-term: dietary protein restriction; oral supplementation with citrulline and nitrogen scavenger drugs, L-lysine-HCl and carnitine; whole-lung lavage to improve respiratory function in persons with pulmonary alveolar proteinosis.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: Long-term protein restriction and administration of citrulline and nitrogen scavenging drugs.</p>
          <p><italic toggle="yes">Prevention of secondary complications</italic>: Varicella immunization in those without previous history of chickenpox or varicella zoster; treatment of those exposed as immune-compromised persons.</p>
          <p><italic toggle="yes">Surveillance</italic>: Plasma concentration of amino acids to identify deficiencies of essential amino acids secondary to protein-restricted diet; fasting and postprandial blood ammonia concentrations and attention to signs of hyperammonemia, urinary orotic acid excretion; periodic evaluation of renal function; evaluation of lung involvement.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Complete restriction of protein for more than 24-48 hours.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk</italic>: Molecular genetic testing or biochemical testing for early diagnosis and treatment of at-risk sibs.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>LPI is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible using molecular genetic techniques if both pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="lpi.Diagnosis">
        <title>Diagnosis</title>
        <sec id="lpi.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of lysinuric protein intolerance (LPI) relies on clinical and biochemical findings [<xref ref-type="bibr" rid="lpi.REF.simell.2001">Simell 2001</xref>] and, recently, on molecular genetic testing.</p>
          <p>LPI typically presents after weaning of breast-fed or formula-fed infants as a variable and nonspecific progressive clinical picture that includes the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Recurrent vomiting with episodes of diarrhea</p>
            </list-item>
            <list-item>
              <p>Episodes of stupor and coma after a protein-rich meal</p>
            </list-item>
            <list-item>
              <p>Poor feeding</p>
            </list-item>
            <list-item>
              <p>Aversion to protein-rich food</p>
            </list-item>
            <list-item>
              <p>Failure to thrive</p>
            </list-item>
            <list-item>
              <p>Enlargement of the liver and spleen</p>
            </list-item>
            <list-item>
              <p>Muscular hypotonia</p>
            </list-item>
          </list>
          <p>The diagnosis of LPI is usually not suspected by clinical findings alone and may be missed during infancy and childhood unless the presence of neurologic involvement triggers a diagnostic laboratory evaluation that includes determination of plasma ammonia concentration. In some cases, the diagnosis is established in adulthood. Over time, additional clinical findings or clinical presentations appear:</p>
          <list list-type="bullet">
            <list-item>
              <p>Poor growth</p>
            </list-item>
            <list-item>
              <p>Early (often severe) osteoporosis</p>
            </list-item>
            <list-item>
              <p>Subclinical or overt pulmonary involvement</p>
            </list-item>
            <list-item>
              <p>Renal involvement</p>
            </list-item>
            <list-item>
              <p>Hemophagocytic lymphohistiocytosis/macrophagic activation syndrome</p>
            </list-item>
          </list>
        </sec>
        <sec id="lpi.Testing">
          <title>Testing</title>
          <sec id="lpi.Biochemical_Testing">
            <title>Biochemical Testing</title>
            <p>
              <bold>Affected individuals</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Plasma ammonia concentration</bold> may be elevated after a protein-rich meal. Fasting values are usually normal.</p>
              </list-item>
              <list-item>
                <p><bold>Urinary orotic acid excretion</bold> is frequently increased.</p>
                <p>Note: (1) In some affected individuals elevated urinary orotic acid excretion occurs in the absence of hyperammonemia. (2) Urinary orotic acid excretion may be within the normal range if an untreated person has had a prolonged fast or has excluded protein-rich food from the diet.</p>
              </list-item>
              <list-item>
                <p>
                  <bold>Plasma amino acid concentrations</bold>
                </p>
                <list list-type="bullet">
                  <list-item>
                    <p>Cationic amino acid (lysine, arginine, and ornithine) concentrations are usually below normal for age, but may be within the normal range.</p>
                  </list-item>
                  <list-item>
                    <p>Serine, glycine, citrulline, proline, alanine, and glutamine concentrations are increased.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Urinary amino acid excretion.</bold> Twenty-four-hour urinary excretion of cationic amino acids, especially lysine, is increased.</p>
                <p>Note: (1) In some affected individuals, calculation of the renal clearances of cationic amino acids (lysine, arginine, and ornithine) may be necessary to clarify the urinary loss of these amino acids. (2) Renal clearance of an amino acid is calculated using the same formula as for creatinine clearance, but substituting creatinine values with values of 24-hour urinary amino acid excretion and of the fasting plasma amino acid concentrations. (3) Mean values and ranges of the renal clearances of cationic amino acids in individuals with LPI are reported in <xref ref-type="bibr" rid="lpi.REF.simell.2001">Simell [2001]</xref>. (4) Serine, glycine, citrulline, proline, alanine, and glutamine are found in excess in urine but have normal renal clearances.</p>
              </list-item>
              <list-item>
                <p>
                  <bold>Other</bold>
                </p>
                <list list-type="bullet">
                  <list-item>
                    <p>Plasma concentrations of thyroxine-binding globulin (TBG), LDH, and ferritin are usually elevated.</p>
                  </list-item>
                  <list-item>
                    <p>Normochromic or hypochromic anemia, leukopenia, and thrombocytopenia are nonspecific hematologic findings.</p>
                  </list-item>
                  <list-item>
                    <p>Hypertriglyceridemia and hypercholesterolemia are frequently observed.</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p><bold>Carriers.</bold> Biochemical analyses cannot be used to determine carrier status.</p>
          </sec>
          <sec id="lpi.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">SLC7A7</italic> is currently the only gene in which pathogenic variants are known to cause LPI [<xref ref-type="bibr" rid="lpi.REF.borsani.1999.297">Borsani et al 1999</xref>, <xref ref-type="bibr" rid="lpi.REF.torrents.1999.293">Torrents et al 1999</xref>].</p>
            <table-wrap id="lpi.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Lysinuric Protein Intolerance</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">SLC7A7</italic>
                    </td>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants in coding and splice sites including the Finnish founder variant</td>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">95%&#x000a0;<sup>5</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Targeted analysis for pathogenic variants</td>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Finnish founder variant <xref ref-type="table" rid="lpi.T.selected_slc7a7_pathogenic_variant">c.895-2A&#x0003e;T</xref>&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">100% for targeted pathogenic variant</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions</td>
                    <td headers="hd_h_lpi.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">15%-20% in non-Finnish populations</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="lpi.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="lpi" object-id="lpi.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="lpi.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="lpi.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="lpi.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="lpi.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="lpi.TF.1.5">
                  <label>5. </label>
                  <p>Presently, of 236 alleles of persons in whom LPI is suspected, only 12 have not been characterized, giving a detection rate of about 95%.</p>
                </fn>
                <fn id="lpi.TF.1.6">
                  <label>6. </label>
                  <p>The pathogenic variant <xref ref-type="table" rid="lpi.T.selected_slc7a7_pathogenic_variant">c.895-2A&#x0003e;T</xref> is the most frequent as a result of a founder effect originating in the Finnish population; this variant is very rare elsewhere. (See <xref ref-type="sec" rid="lpi.Molecular_Genetics">Molecular Genetics</xref> for other recurrent pathogenic variants).</p>
                </fn>
                <fn id="lpi.TF.1.7">
                  <label>7. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Deletion/duplication analysis</bold>. Several groups have reported pathogenic deletions and duplications of <italic toggle="yes">SLC7A7</italic> [<xref ref-type="bibr" rid="lpi.REF.kamada.2001.717">Kamada et al 2001</xref>, <xref ref-type="bibr" rid="lpi.REF.shoji.2002.375">Shoji et al 2002</xref>, <xref ref-type="bibr" rid="lpi.REF.sperandeo.2005.410">Sperandeo et al 2005</xref>].When the multiplex ligation-dependent probe amplification (MLPA) assay was used to screen for copy number changes of <italic toggle="yes">SLC7A7</italic> in individuals with LPI, two deletions of 12 kb and 4.6 kb were identified that resulted from an Alu-mediated recombination [<xref ref-type="bibr" rid="lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</xref>]. The number of rearrangements found in this study is higher than that previously reported in non-Finnish groups (i.e., 21.4% vs 5.1%) [<xref ref-type="bibr" rid="lpi.REF.cimbalistiene.2007.277">Cimbalistiene et al 2007</xref>, <xref ref-type="bibr" rid="lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</xref>].</p>
          </sec>
        </sec>
        <sec id="lpi.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> If clinical and biochemical findings are suggestive of LPI, the diagnosis can be confirmed by molecular genetic testing of <italic toggle="yes">SLC7A7.</italic></p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing begins with sequence analysis of <italic toggle="yes">SLC7A7</italic>. If no pathogenic variant or only one pathogenic variant is identified, deletion/duplication analysis is performed. The identification of two mutated alleles confirms the diagnosis of LPI.</p>
              <p>Note: Testing may begin with targeted analysis for the Finnish founder variant, <xref ref-type="table" rid="lpi.T.selected_slc7a7_pathogenic_variant">c.895-2A&#x0003e;T</xref>, in individuals of Finnish ancestry. For individuals of other ancestry, targeted analysis for a known recurrent pathogenic variant in those populations may be performed (see <xref ref-type="sec" rid="lpi.Molecular_Genetics">Molecular Genetics</xref>, <bold>Pathogenic variants</bold>).</p>
            </list-item>
            <list-item>
              <p>When only one mutated allele is detected, clinical and biochemical findings are crucial to the diagnosis of LPI.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="lpi.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="lpi.Clinical_Description">
          <title>Clinical Description</title>
          <p>Usually infants with lysinuric protein intolerance (LPI) present with gastrointestinal symptoms (feeding difficulties, vomiting, and diarrhea) soon after weaning from breast milk or formula.</p>
          <p>Most affected infants show failure to thrive early in life. Neurologic presentation with episodes of coma is less common. Moderate hepatosplenomegaly is present. Muscular hypotonia and hypotrophy are observed from early infancy. Poor growth and delayed skeletal maturation are common after the first year of life. Osteoporosis may result in pathologic fractures.</p>
          <p>Mental development is normal unless episodes of prolonged coma cause neurologic damage.</p>
          <p>Classic symptoms of protein intolerance may remain unnoticed during the first and second decades of life because of subconscious avoidance of dietary protein.</p>
          <p>Treatment with a low-protein diet and supplementation with citrulline and nitrogen-scavenging drugs (see Management, <xref ref-type="sec" rid="lpi.Treatment_of_Manifestations">Treatment of Manifestations</xref>) significantly improve symptoms related to the metabolic abnormality. However, some complications, representing the major causes of morbidity and mortality, are not amenable to treatment.</p>
        </sec>
        <sec id="lpi.Complications">
          <title>Complications</title>
          <p><bold>Lung disease.</bold> Progressive interstitial changes in the lung are frequently detected from early years without overt clinical symptoms. Progression to severe pulmonary alveolar proteinosis (PAP) is a well-known life-threatening complication.</p>
          <p>PAP usually presents with progressive exertional dyspnea, tachypnea, and cough that are exacerbated by respiratory infections. Diminished breath sounds, inspiratory crackles, subcostal and suprasternal retractions, cyanosis and, more rarely, digital clubbing can be found on physical examination.</p>
          <p>Diffuse reticulonodular densities are common on radiologic evaluation. Chest high-resolution computed tomography reveals ground-glass opacities with superimposed smooth septal thickening.</p>
          <p>The pathogenesis of the PAP in LPI is poorly understood.</p>
          <p><bold>Renal involvement.</bold> Glomerular and tubular involvement is common. Isolated mild proteinuria is the initial sign of renal disease. Serum creatinine concentration and cystatin C concentration are frequently increased. In a study on 39 Finnish individuals with LSI, proteinuria and hematuria were observed in 74% and 38%, respectively. Elevated blood pressure, mild to moderate renal insufficiency and, in some cases, end-stage renal disease were also reported in this cohort [<xref ref-type="bibr" rid="lpi.REF.tanner.2007.631">Tanner et al 2007</xref>].</p>
          <p>Renal tubular acidosis or findings consistent with reduced phosphate reabsorption and generalized aminoaciduria indicate underlying complex proximal tubular disease (<related-object link-type="booklink" source-id="gene" document-id="fa" document-type="chapter">Fanconi syndrome</related-object>).</p>
          <p>Kidney histology reveals immune-mediated glomerulonephritis as well as chronic tubulointerstitial nephritis with glomerulosclerosis in the absence of immune deposits.</p>
          <p>The pathogenesis of the renal involvement is unknown.</p>
          <p><bold>Hematologic complications and bone marrow anomalies.</bold> A clinical presentation resembling hemophagocytic lymphohistiocytosis/macrophagic activation syndrome has been repeatedly observed.</p>
          <p>Erythroblastophagocytosis and decreased megakaryocytes may be found in bone marrow aspirate. Hematologic findings also include slight normochromic or hypochromic anemia, leukopenia, thrombocytopenia, and sub-clinical intravascular coagulation.</p>
          <p><bold>Hypercholesterolemia and hypertriglyceridemia.</bold> Increased plasma concentrations of cholesterol and triglycerides are relatively common in individuals with LPI [<xref ref-type="bibr" rid="lpi.REF.tanner.2010.s145">Tanner et al 2010</xref>]. No clear explanation has been proposed for this dyslipidemic state; a higher-carbohydrate diet may contribute to the increased plasma concentration of triglycerides, but it is not sufficient to explain either the hypercholesterolemia or the severe hypertriglyceridemia (triglycerides &#x0003e;1,000 mg/dL or &#x0003e;11 mmol/L).</p>
          <p><bold>Autoimmunity and immunologic abnormalities.</bold> Various immunologic abnormalities including impaired function of lymphocytes, the presence of lupus erythematosus (LE) cells, antinuclear and anti-DNA antibodies, hypergammaglobulinemia or low serum immune globulin concentrations, hypocomplementemia, and life-threatening varicella infection can be observed.</p>
          <p><bold>Growth, growth hormone (GH) deficiency.</bold> Growth retardation is commonly observed in children with LPI and is usually related to protein malnutrition. In some cases, growth hormone deficiency or arginine depletion causing impaired secretion of growth hormone is observed [<xref ref-type="bibr" rid="lpi.REF.esposito.2006.763">Esposito et al 2006</xref>].</p>
          <p><bold>Pancreatitis.</bold> Acute pancreatitis is a life-threatening complication in some persons with LPI. A clear relationship with severe hypertriglyceridemia has not been defined.</p>
          <p><bold>Pregnancy and childbirth.</bold> A Finnish study demonstrated that maternal LPI is associated with increased risk of anemia and toxemia during pregnancy and increased risk of bleeding complications during delivery. Intrauterine growth retardation was noted in a significant number of unaffected neonates born to mothers with LPI [<xref ref-type="bibr" rid="lpi.REF.tanner.2006.224">Tanner et al 2006</xref>].</p>
          <p><bold>Pathophysiology.</bold> LPI is an inborn error of metabolism caused by mutation of <italic toggle="yes">SLC7A7</italic>, the gene encoding the light chain of system y<sup>+</sup>L. This system mediates the transport of cationic amino acids at the basolateral membrane of enterocytes and renal tubular cells. Most of the clinical findings of LPI may be related to the metabolic abnormality originating from altered absorption and reabsorption of cationic amino acids. In this respect, hyperammonemia is caused by functional impairment of the urea cycle probably resulting from an intracellular deficiency of ornithine in the liver. However, nutritional imbalance of cationic amino acids does not explain the complex multiorgan involvement of LPI, especially the complications affecting lung, kidney, and immune and hematologic systems.</p>
          <p>System y<sup>+</sup>L activity has recently been shown to be markedly reduced in monocytes and alveolar macrophages from an individual with LPI [<xref ref-type="bibr" rid="lpi.REF.barilli.2010.32">Barilli et al 2010</xref>]. This could explain the pathogenesis of the severe complications of LPI including those affecting lung and kidney. A paradox may occur in LPI: on one hand, mutation of <italic toggle="yes">SLC7A7</italic> causes a general depletion of cationic amino acid secondary to defective intestinal uptake and renal reuptake; additionally, in immunocompetent cells the impairment of system y<sup>+</sup>L activity may cause intracellular arginine accumulation, with a potential risk of surcharging the nitric oxide pathway [<xref ref-type="bibr" rid="lpi.REF.sebastio.2011.54">Sebastio et al 2011</xref>]. A lower dosage of citrulline supplementation is now recommended, given that citrulline is converted into arginine, notably in kidney.</p>
        </sec>
        <sec id="lpi.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations have not been found.</p>
          <p>Variable expressivity is observed in individuals of Finnish origin who are homozygous for the same founder variant.</p>
          <p>In a large Italian pedigree, homozygosity for the same private variant <xref ref-type="table" rid="lpi.T.selected_slc7a7_pathogenic_variant">c.1381_1384dupATCA</xref> gave rise to different clinical presentations: severe short stature with pancreatic and renal involvement in a girl; early pulmonary alveolar proteinosis causing death in a boy; a very mild clinical presentation in another boy whose brother had a similar clinical picture but died suddenly after a flu-like episode [<xref ref-type="bibr" rid="lpi.REF.sperandeo.2000.92">Sperandeo et al 2000</xref>].</p>
          <p>The pathogenic variant <xref ref-type="table" rid="lpi.T.selected_slc7a7_pathogenic_variant">c.726G&#x0003e;A</xref> (p.Trp242Ter) was found in 13 individuals belonging to nine independent families from Italy, Morocco, and North Africa. Five of the 13 had a severe phenotype with pulmonary alveolar proteinosis [<xref ref-type="bibr" rid="lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</xref>].</p>
        </sec>
        <sec id="lpi.Prevalence">
          <title>Prevalence</title>
          <p>Over 140 individuals with LPI have been reported; one third are of Finnish origin [<xref ref-type="bibr" rid="lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</xref>, <xref ref-type="bibr" rid="lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</xref>]. Clusters of affected individuals have also been isolated in southern Italy and Japan.</p>
          <p>The disorder is found worldwide: individuals with LPI originate from at least 25 countries [<xref ref-type="bibr" rid="lpi.REF.cimbalistiene.2007.277">Cimbalistiene et al 2007</xref>, <xref ref-type="bibr" rid="lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</xref>, <xref ref-type="bibr" rid="lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</xref>]. A founder effect for specific alleles underlies the observed occurrence of LPI in Finland (<xref ref-type="table" rid="lpi.T.selected_slc7a7_pathogenic_variant">c.895-2A&#x0003e;T</xref>) and in Japan (<xref ref-type="table" rid="lpi.T.selected_slc7a7_pathogenic_variant">c.1228C&#x0003e;T</xref>).Surprisingly, this pathogenic variant was also found in a Moroccan individual [<xref ref-type="bibr" rid="lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</xref>].</p>
          <p>The incidence has been estimated at 1:60,000 newborns in Finland and 1:57,000 in Japan [<xref ref-type="bibr" rid="lpi.REF.koizumi.2000.270">Koizumi et al 2000</xref>].</p>
          <p>Newborn screening in northern Japan revealed a carrier rate of 1:119 [<xref ref-type="bibr" rid="lpi.REF.koizumi.2000.270">Koizumi et al 2000</xref>].</p>
        </sec>
      </sec>
      <sec id="lpi.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are known to be associated with mutation of <italic toggle="yes">SLC7A7</italic>.</p>
      </sec>
      <sec id="lpi.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The phenotypic variability of lysinuric protein intolerance (LPI) has resulted in various misdiagnoses.</p>
        <p><bold>Hyperammonemia.</bold> Hyperammonemia and clinical manifestations related to it are shared by other metabolic diseases, notably the urea cycle disorders (see <related-object link-type="booklink" source-id="gene" document-id="ucd-overview" document-type="chapter">Urea Cycle Disorders Overview</related-object>). Increased orotic aciduria and hyperexcretion of cationic amino acids help to distinguish LPI from other hyperammonemic conditions.</p>
        <p><bold>Lysosomal storage diseases (LSDs).</bold> Hepatosplenomegaly, interstitial lung disease, and hematologic manifestation may suggest LSDs such as <related-object link-type="booklink" source-id="gene" document-id="npab" document-type="chapter">Niemann-Pick disease type B</related-object> and <related-object link-type="booklink" source-id="gene" document-id="gaucher" document-type="chapter">Gaucher disease</related-object> [<xref ref-type="bibr" rid="lpi.REF.parenti.1995.246">Parenti et al 1995</xref>].</p>
        <p><bold>Malabsorptive diseases.</bold> The occurrence of gastrointestinal symptoms (e.g., vomiting, diarrhea) as well as of hypoproteinemia and failure to thrive suggests <related-object link-type="booklink" source-id="gene" document-id="celiac" document-type="chapter">celiac disease</related-object>. LPI should be included in the differential diagnosis of malabsorptive diseases.</p>
        <p><bold>Hemophagocytic lymphohistiocytosis/macrophagic activation syndrome.</bold> Failure to thrive, hepatosplenomegaly, fever, hypertriglyceridemia, increased serum ferritin concentration, anemia, and other blood abnormalities suggest acquired or <related-object link-type="booklink" source-id="gene" document-id="hlh" document-type="chapter">familial hemophagocytic lymphohistiocytosis</related-object>.</p>
        <p><bold>Autoimmune disorders.</bold> Clinical and biochemical findings consistent with diagnosis of an autoimmune disorder such as systemic lupus erythematosus (SLE) were reported in individuals with LPI and, in some cases, were the presenting features.</p>
      </sec>
      <sec id="lpi.Management">
        <title>Management</title>
        <sec id="lpi.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with lysinuric protein intolerance, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>History for evidence of hyperammonemic crises with overt neurologic manifestations (vomiting, drowsiness, coma) and of respiratory involvement (cough, dyspnea, recurrent lower respiratory tract infections)</p>
            </list-item>
            <list-item>
              <p>Neurologic evaluation to detect secondary neurologic damage</p>
            </list-item>
            <list-item>
              <p>Respiratory evaluation including chest x-ray, pulmonary high-resolution computed tomography, and function tests</p>
            </list-item>
            <list-item>
              <p>Evaluation and follow-up of growth parameters</p>
            </list-item>
            <list-item>
              <p>Liver and spleen ultrasound examination to monitor liver structural changes and spleen enlargement</p>
            </list-item>
            <list-item>
              <p>Hematologic evaluation (bone marrow aspirate may be required)</p>
            </list-item>
            <list-item>
              <p>Immunologic assessment including plasma concentrations of immune globulins and, when clinically indicated, detection of autoimmune antibodies and immune complexes</p>
            </list-item>
            <list-item>
              <p>Renal function studies</p>
            </list-item>
            <list-item>
              <p>Bone density evaluation</p>
            </list-item>
          </list>
        </sec>
        <sec id="lpi.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The management of individuals with LPI is similar to that described in <related-object link-type="booklink" source-id="gene" document-id="ucd-overview" document-type="chapter">urea cycle disorders</related-object>. In LPI, the severity of hyperammonemic crises rarely requires extreme treatments such as dialysis and hemofiltration. It is recommended that individuals with LPI be cared for by a specialized metabolic team.</p>
          <sec id="lpi.Treatment_of_Acute_Hyperammonemic_Cr">
            <title>Treatment of Acute Hyperammonemic Crises</title>
            <p><bold>Pharmacologic management.</bold> Blocking the production of ammonia is accomplished by the intravenous administration of arginine chloride and of a combination of the nitrogen scavenger drugs sodium phenylacetate and sodium benzoate. An intravenous loading dose is followed by an oral maintenance dose of nitrogen scavenger drugs when the individual is stable. Depletion of branched chain amino acids (BCAAs) may occur as a consequence of the therapy with sodium phenylacetate [<xref ref-type="bibr" rid="lpi.REF.scaglia.2010.s72">Scaglia 2010</xref>]. Persistence of BCAA deficiency hampers protein synthesis and induces catabolism. Therefore, careful evaluation of BCAA serum levels is recommended and specific supplementation may be required. Various detailed protocols for the treatment of intercurrent hyperammonemia in individuals with urea cycle disorders and, more generally, with hyperammonemia may be adopted [<xref ref-type="bibr" rid="lpi.REF.singh.2007.880">Singh 2007</xref>, <xref ref-type="bibr" rid="lpi.REF.h_berle.2011.21">H&#x000e4;berle 2011</xref>].</p>
            <p><bold>Reducing the amount of excess nitrogen in the diet and reducing catabolism through the introduction of energy supplied by carbohydrates and fat.</bold> In acutely ill individuals, energy should be provided as carbohydrate and fat, either intravenously as glucose and Intralipid<sup>&#x000ae;</sup> or orally as protein-free formula.</p>
            <p>Patients should be transitioned from parenteral to enteral feeds as soon as possible. Nasogastric tube feeding may be required to ensure adequate caloric and nutritional intake. Therapy with ondansetron can be started to decrease vomiting.</p>
            <p>Complete restriction of protein for more than 24-48 hours is not recommended as the individual will become protein catabolic for essential amino acids.</p>
          </sec>
          <sec id="lpi.LongTerm_Treatment">
            <title>Long-Term Treatment</title>
            <p><bold>Dietary protein restriction and citrulline supplementation.</bold> Current treatment consists of dietary protein restriction (0.8-1.5 g/kg/day in children and 0.5-0.8 g/kg/day in adults) and supplementation with citrulline (100 mg/kg/day, in four doses taken with meals). Nitrogen scavenger drugs such as sodium benzoate (100-250 mg/kg/day in four divided doses) should be added to keep the lowest effective dosage of citrulline. As in the management of other inherited metabolic disorders, diet must be tailored on the basis of individual tolerance for the protein charge and carefully monitored to avoid disturbances of both growth and nutritional status.</p>
            <p>Measurement of orotic aciduria appears to be a sensitive tool for adjustment of treatment.</p>
            <p><bold>Lysine supplementation.</bold> As lysine deficiency may contribute to the development of pathologic signs in LPI, oral supplementation with L-lysine-HCl should be attempted. Taking into account the defective intestinal absorption of lysine in LPI, small doses of L-lysine-HCl (0.05-0.5 mmol/kg, three times per day) are given and may normalize plasma lysine concentrations [<xref ref-type="bibr" rid="lpi.REF.lukkarinen.2003.935">Lukkarinen et al 2003</xref>].</p>
            <p><bold>Carnitine supplemetation.</bold> In a recent survey of 37 Finnish patients, hypocarnitemia was found to be associated with female sex, renal insufficiency, and the use of ammonia-scavenging drugs. When documented, hypocarnitemia should be corrected (25-50 mg/kg/day) [<xref ref-type="bibr" rid="lpi.REF.korman.2002.81">Korman et al 2002</xref>, <xref ref-type="bibr" rid="lpi.REF.tanner.2008.549">Tanner et al 2008</xref>].</p>
            <p><bold>Additional therapies.</bold> Modification of the diet and fish oil supplementation should be tried in individuals with dyslipidemia before pharmacologic treatment of dyslipidemia is started.</p>
          </sec>
          <sec id="lpi.Treatment_of_Late_Complications">
            <title>Treatment of Late Complications</title>
            <p>While hyperammonemia can be efficiently prevented and treated, no effective therapy has been established for late complications.</p>
            <p><bold>Treatment of lung disease</bold> in LPI remains controversial: high-dose corticosteroid treatment was effective in a few patients when started early, whereas no response was noted in others.</p>
            <p>In individuals with pulmonary alveolar proteinosis (PAP), treatment with granulocyte/monocyte colony stimulating factor (GM-CSF) was shown to be ineffective or even to worsen the clinical course [<xref ref-type="bibr" rid="lpi.REF.santamaria.2004.268">Santamaria et al 2004</xref>]. Recently, increased GM-CSF and decreased bioavailability of surfactant protein D have been proposed as a part of the mechanism underlying PAP in LPI [<xref ref-type="bibr" rid="lpi.REF.douda.2009.29">Douda et al 2009</xref>]. Whole lung lavage still remains the best therapeutic approach for PAP in LPI [<xref ref-type="bibr" rid="lpi.REF.ceruti.2007.14">Ceruti et al 2007</xref>]; however, relapses may require serial lavage.</p>
            <p>Heart-lung transplantation was attempted with a temporary successful result, but it did not prevent a fatal return of the lung disease [<xref ref-type="bibr" rid="lpi.REF.santamaria.2004.268">Santamaria et al 2004</xref>].</p>
            <p>Bone marrow transplantation has been discussed as a possible treatment for PAP in LPI. The rationale of this therapeutic approach would rely on the hypothesis of a defective function of lung macrophages [<xref ref-type="bibr" rid="lpi.REF.barilli.2010.32">Barilli et al 2010</xref>, <xref ref-type="bibr" rid="lpi.REF.sebastio.2011.54">Sebastio et al 2011</xref>].</p>
            <p><bold>Treatment of renal disease</bold> in LPI should follow the standard guidelines under direction of the nephrologist.</p>
            <p><bold>Treatment of hemophagocytic lymphohistiocytosis/macrophagic activation syndrome</bold> in LPI should be planned under the direction of the specialist.</p>
          </sec>
        </sec>
        <sec id="lpi.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>The prevention of metabolic abnormality is the goal of the treatment. Long-term management is based on protein-restricted diet and administration of citrulline (see <xref ref-type="sec" rid="lpi.Treatment_of_Manifestations">Treatment of Manifestations</xref>).</p>
        </sec>
        <sec id="lpi.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>The onset and the clinical course of the secondary complications, such as lung and renal involvement, seem to be poorly influenced by early treatment.</p>
          <p>Efforts to minimize the risk of respiratory infections should be promoted.</p>
          <p>An individual with LPI without previous history of chickenpox or varicella zoster should be vaccinated or, if exposed to varicella, treated as an immune-compromised person.</p>
          <p>Some individuals with LPI may respond poorly to polysaccharide-containing vaccines. Therefore, revaccination may be required if specific antibody titers are non-protective.</p>
        </sec>
        <sec id="lpi.Surveillance">
          <title>Surveillance</title>
          <p>Individuals with LPI should be referred for follow-up to physicians with expertise in the treatment of inborn errors of metabolism. The age of the patient and the severity of the clinical features determine the frequency of clinical visits and monitoring.</p>
          <p>Monitoring should include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Plasma concentrations of amino acids to identify deficiencies of essential amino acids induced by the protein-restricted diet (similar to that used in <related-object link-type="booklink" source-id="gene" document-id="ucd-overview" document-type="chapter">urea cycle disorders</related-object>)</p>
            </list-item>
            <list-item>
              <p>Attention to early signs of hyperammonemia including lethargy, nausea, vomiting, and poor feeding in young children, and headache and mood changes in older children</p>
            </list-item>
            <list-item>
              <p>Fasting and postprandial blood ammonia concentrations</p>
            </list-item>
            <list-item>
              <p>Urinary orotic acid excretion</p>
            </list-item>
            <list-item>
              <p>Evaluation of renal function</p>
            </list-item>
            <list-item>
              <p>Attention to early clinical signs of lung involvement</p>
            </list-item>
            <list-item>
              <p>Serum concentrations of LDH and ferritin</p>
            </list-item>
          </list>
          <p>The development of a multiorgan pathology in LPI requires careful surveillance of several complications including lung and renal diseases and osteoporosis. No specific guidelines have been proposed. Therefore, a tailored approach is necessary for the follow-up of a specific complication.</p>
        </sec>
        <sec id="lpi.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Large boluses of protein or amino acids should be avoided.</p>
          <p>It is not clear whether prolonged fasting may trigger hyperammonemic crises.</p>
        </sec>
        <sec id="lpi.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>If the pathogenic variants have been identified in an affected family member, it is appropriate to offer molecular genetic testing to at-risk sibs in order to reduce morbidity and mortality through early diagnosis and treatment.</p>
          <p>When molecular testing is not available, early diagnosis of at-risk sibs relies on careful clinical evaluation and determination of plasma and urinary amino acid concentrations and orotic acid urinary excretion.</p>
          <p>See <xref ref-type="sec" rid="lpi.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="lpi.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><bold>Alendronate.</bold> Osteopenia leading to osteoporosis is a major feature of LPI. Many individuals with LPI show osteopenia or osteoporosis despite treatment. Treatment with alendronate has recently been attempted in a child with LPI [<xref ref-type="bibr" rid="lpi.REF.g_mez.2006.687">G&#x000f6;mez et al 2006</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="lpi.Other">
          <title>Other</title>
          <p>No treatment, including strict compliance with dietary regimen, citrulline supplementation, or high-dose corticosteroids, is effective in influencing the clinical course of the renal disease.</p>
        </sec>
      </sec>
      <sec id="lpi.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="lpi.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Lysinuric protein intolerance (LPI) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="lpi.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one mutated allele.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with LPI are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">SLC7A7</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="lpi.Carrier_Detection">
          <title>Carrier Detection</title>
          <p><bold>Molecular genetic testing.</bold> Carrier testing for at-risk family members using molecular genetic techniques is possible once the pathogenic variants have been identified in the family.</p>
          <p><bold>Biochemical genetic testing.</bold> Biochemical tests (e.g., plasma concentration of amino acids or urinary excretion of orotic acid) cannot distinguish carriers from controls.</p>
        </sec>
        <sec id="lpi.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="lpi.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="lpi.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">SLC7A7</italic> pathogenic variants have been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for LPI are possible.</p>
        </sec>
      </sec>
      <sec id="lpi.Resources">
        <title>Resources</title>
      </sec>
      <sec id="lpi.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC7A7</italic> has 11 exons and is 46.5 kbp in length. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="lpi" object-id="lpi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign variants.</bold> More than 90 benign variants have been identified in intronic regions of <italic toggle="yes">SLC7A7</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/snp/">www.ncbi.nlm.nih.gov/snp/</ext-link>).</p>
        <p><bold>Pathogenic variants.</bold> To date, more than 50 <italic toggle="yes">SLCA7</italic> pathogenic variants have been identified as causative of lysinuric protein intolerance (LPI) [<xref ref-type="bibr" rid="lpi.REF.borsani.1999.297">Borsani et al 1999</xref>, <xref ref-type="bibr" rid="lpi.REF.torrents.1999.293">Torrents et al 1999</xref>, <xref ref-type="bibr" rid="lpi.REF.shoji.2002.375">Shoji et al 2002</xref>, <xref ref-type="bibr" rid="lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</xref>, <xref ref-type="bibr" rid="lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</xref>]. Most pathogenic variants reported in these five studies are private, except for the Finnish founder variant c.895-2A&#x0003e;T found in 38 individuals, the c.726G&#x0003e;A pathogenic variant found in 13, and the c.1228C&#x0003e;T pathogenic variant found in persons of Japanese heritage and one of Moroccan origin.</p>
        <p>All types of pathogenic variants have been observed: missense and nonsense variants, deletions, insertions, splicing variants, and large genomic rearrangements.</p>
        <table-wrap id="lpi.T.selected_slc7a7_pathogenic_variant" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">SLC7A7</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.726G&#x0003e;A&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp242Ter</td>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_003982.3">NM_003982.3</ext-link>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_003973.3">NP_003973.3</ext-link></td>
              </tr>
              <tr>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.895-2A&#x0003e;T&#x000a0;<sup>3</sup><break/>(1181-2A&#x0003e;T or 1136-2A&#x0003e;T)</td>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1228C&#x0003e;T</td>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg410Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1381_1384dupATCA<break/>(1670insATCA or 1384_1385insATCA)</td>
                <td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg462AsnfsTer7</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="lpi.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="lpi.TF.2.2">
              <label>2. </label>
              <p>Described in Italian and North African individuals. See <xref ref-type="sec" rid="lpi.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>.</p>
            </fn>
            <fn id="lpi.TF.2.3">
              <label>3. </label>
              <p>Founder variant of Finnish population; previously reported as 1181-2A&#x0003e;T by <xref ref-type="bibr" rid="lpi.REF.torrents.1999.293">Torrents et al [1999]</xref> and as 1136-2A&#x0003e;T by <xref ref-type="bibr" rid="lpi.REF.borsani.1999.297">Borsani et al [1999]</xref></p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">SLC7A7</italic> encodes the Y<sup>+</sup>L amino acid transporter 1 (y<sup>+</sup>LAT-1) protein; y<sup>+</sup>LAT-1 is linked by a disulfide bond to solute carrier family 3 member 2 (SLC3A2, also known as 4F2hc), which represents the heavy chain subunit of the heterodimeric amino acid transporter defective in LPI. This transporter, located at the basolateral membrane of epithelial cells, induces a system y<sup>+</sup>L activity.</p>
        <p><bold>Abnormal gene product.</bold> Expression studies in cell culture systems demonstrated that the tested <italic toggle="yes">SLC7A7</italic> pathogenic variants are functionally different from the wild type and that most of them abolish the y<sup>+</sup>L activity [<xref ref-type="bibr" rid="lpi.REF.mykk_nen.2000.431">Mykk&#x000e4;nen et al 2000</xref>, <xref ref-type="bibr" rid="lpi.REF.sperandeo.2005.410">Sperandeo et al 2005</xref>].</p>
      </sec>
      <sec id="lpi.References">
        <title>References</title>
        <sec id="lpi.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="lpi.Literature_Cited.reflist0">
            <ref id="lpi.REF.barilli.2010.32">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barilli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rotoli</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visigalli</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bussolati</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gazzola</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadija</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruzza</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luisetti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dall'Asta</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <volume>5</volume>
                <fpage>32</fpage>
                <pub-id pub-id-type="pmid">21110863</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.borsani.1999.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Borsani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bassi</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperandeo</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Grandi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buoninconti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riboni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzoni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Incerti</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballabio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance.</article-title>
                <source>Nat Genet</source>
                <volume>21</volume>
                <fpage>297</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">10080183</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.ceruti.2007.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ceruti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stella</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adami</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolongaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baritussio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pozzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luisetti</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2007</year>
                <volume>2</volume>
                <fpage>14</fpage>
                <pub-id pub-id-type="pmid">17386098</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.cimbalistiene.2007.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cimbalistiene</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehnert</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huoponen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kucinskas</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>First reported case of lysinuric protein intolerance (LPI) in Lithuania, confirmed biochemically and by DNA analysis.</article-title>
                <source>J Appl Genet.</source>
                <volume>48</volume>
                <fpage>277</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">17666782</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.douda.2009.29">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Douda</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farmakovski</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grasemann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palaniyar</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>SP-D counteracts GM-CSF-mediated increase of granuloma formation by alveolar macrophages in lysinuric protein intolerance.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <volume>4</volume>
                <fpage>29</fpage>
                <pub-id pub-id-type="pmid">20030831</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.esposito.2006.763">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Esposito</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lettiero</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fecarotta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salerno</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Growth hormone deficiency in a patient with lysinuric protein intolerance.</article-title>
                <source>Eur J Pediatr</source>
                <volume>165</volume>
                <fpage>763</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16775724</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.fontllitj_s.2009.71">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Font-Llitj&#x000f3;s</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodr&#x000ed;guez-santiago</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sillu&#x000e9;</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ma&#x000f1;as</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rz-Jurado</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palac&#x000ed;n</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nunes</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Novel SLC7A7 large rearrangements in lysinuric protein intolerance patients involving the same AluY repeat.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>17</volume>
                <fpage>71</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18716612</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.g_mez.2006.687">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000f6;mez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Cazorla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artuch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varea</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinillos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilaseca</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Treatment of severe osteoporosis with alendronate in a patient with lysinuric protein intolerance.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>29</volume>
                <fpage>687</fpage>
                <pub-id pub-id-type="pmid">16868861</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.h_berle.2011.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>H&#x000e4;berle</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>The management of hyperammonemia.</article-title>
                <source>Eur J Pediatr</source>
                <volume>170</volume>
                <fpage>21</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">21165747</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.kamada.2001.717">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kamada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagaretani</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maruyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hiraoka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inui</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kayanoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuzawa</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Vascular endothelial dysfunction resulting from L-arginine deficiency in a patient with lysinuric protein intolerance.</article-title>
                <source>J Clin Invest.</source>
                <year>2001</year>
                <volume>108</volume>
                <fpage>717</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">11544277</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.koizumi.2000.270">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koizumi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoji</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nozaki</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>A, E X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dakeishi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuyoshi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasuhiko</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manabe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takasago</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect. The Mass Screening Group.</article-title>
                <source>Hum Mutat</source>
                <volume>16</volume>
                <fpage>270</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">10980538</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.korman.2002.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raas-Rothschild</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutman</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Hypocarnitinemia in lysinuric protein intolerance.</article-title>
                <source>Mol Genet Metab</source>
                <volume>76</volume>
                <fpage>81</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">12175786</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.lukkarinen.2003.935">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lukkarinen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nanto-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulkki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aalto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Oral supplementation corrects plasma lysine concentrations in lysinuric protein intolerance.</article-title>
                <source>Metabolism</source>
                <volume>52</volume>
                <fpage>935</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12870174</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.mykk_nen.2000.431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mykk&#x000e4;nen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torrents</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pineda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camps</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoldi</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horelli-Kuitunen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huoponen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinonen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oksanen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savontaus</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palac&#x000ed;n</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aula</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Functional analysis of novel mutations in y(+)LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI)</article-title>
                <source>Hum Mol Genet.</source>
                <year>2000</year>
                <volume>9</volume>
                <fpage>431</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10655553</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.parenti.1995.246">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Incerti</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pecoraro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terracciano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course.</article-title>
                <source>J Pediatr</source>
                <volume>126</volume>
                <fpage>246</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">7844671</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.santamaria.2004.268">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santamaria</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brancaccio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francalanci</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Squitieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'argenio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parisi</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance.</article-title>
                <source>J Pediatr</source>
                <volume>145</volume>
                <fpage>268</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">15289783</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.scaglia.2010.s72">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>New insights in nutritional management and amino acid supplementation in urea cycle disorders.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>100</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S72</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20299258</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.sebastio.2011.54">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperandeo</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Lysinuric protein intolerance: reviewing concepts on a multisystem disease.</article-title>
                <source>Am J Med Genet C Semin Med Genet.</source>
                <year>2011</year>
                <volume>157C</volume>
                <fpage>54</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">21308987</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.shoji.2002.375">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shoji</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoji</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsumori</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takasago</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takayanagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ihara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaji</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koizumi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hokezu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagamatsu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mikami</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitajima</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Five novel SLC7A7 variants and y+L gene-expression pattern in cultured lymphoblasts from Japanese patients with lysinuric protein intolerance.</article-title>
                <source>Hum Mutat</source>
                <volume>20</volume>
                <fpage>375</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">12402335</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.simell.2001">
              <mixed-citation publication-type="book">Simell O. Lysinuric protein intolerance and other cationic aminoacidurias. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. Chap 192. New York, NY: McGraw-Hill. 2001:4933-56.</mixed-citation>
            </ref>
            <ref id="lpi.REF.singh.2007.880">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Nutritional management of patients with urea cycle disorders</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>30</volume>
                <fpage>880</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18034368</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.sperandeo.2000.92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sperandeo</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bassi</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riboni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buoninconti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzoni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Incerti</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larocca</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dianzani</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Candito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Endo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballabio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borsani</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Structure of the SLC7A7 gene and mutational analysis of patients affected by lysinuric protein intolerance.</article-title>
                <source>Am J Hum Genet</source>
                <volume>66</volume>
                <fpage>92</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10631139</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.sperandeo.2005.410">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sperandeo</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Annunziata</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ammendola</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiorito</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soldovieri</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taglialatela</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Lysinuric protein intolerance: identification and functional analysis of mutations of the SLC7A7 gene.</article-title>
                <source>Hum Mutat</source>
                <volume>25</volume>
                <fpage>410</fpage>
                <pub-id pub-id-type="pmid">15776427</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.sperandeo.2008.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sperandeo</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Lysinuric protein intolerance: Update and extended mutation analysis of the SLC7A7 gene.</article-title>
                <source>Hum Mutat</source>
                <volume>29</volume>
                <fpage>14</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">17764084</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.tanner.2006.224">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tanner</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nanto-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niinikoski</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erkkola</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huoponen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hazards associated with pregnancies and deliveries in lysinuric protein intolerance.</article-title>
                <source>Metabolism</source>
                <volume>55</volume>
                <fpage>224</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">16423630</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.tanner.2007.631">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tanner</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niinikoski</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jahnukainen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keskinen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saha</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kananen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helanter&#x000e4;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linnanvuo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huoponen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance.</article-title>
                <source>J Pediatr</source>
                <volume>150</volume>
                <fpage>631</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17517249</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.tanner.2008.549">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tanner</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rashed</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kotilainen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aalto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venetoklis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niinikoski</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huoponen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Carnitine deficiency and L-carnitine supplementation in lysinuric protein intolerance.</article-title>
                <source>Metabolism</source>
                <volume>57</volume>
                <fpage>549</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">18328359</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.tanner.2010.s145">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tanner</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niinikoski</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>N&#x000e4;nt&#x000f6;-Salonen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Combined hyperlipidemia in patients with lysinuric protein intolerance.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>33</volume>
                <supplement>Suppl 3</supplement>
                <fpage>S145</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">20177788</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.torrents.1999.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Torrents</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mykkanen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pineda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feliubadalo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estevez</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Cid</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanjurjo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nunes</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huoponen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinikainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simell</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savontaus</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aula</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palacin</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene.</article-title>
                <source>Nat Genet</source>
                <volume>21</volume>
                <fpage>293</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10080182</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="lpi.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="lpi.Suggested_Reading.reflist0">
            <ref id="lpi.REF.br_er.2008.249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Br&#x000f6;er</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Amino acid transport across mammalian intestinal and renal epithelia.</article-title>
                <source>Physiol Rev.</source>
                <volume>88</volume>
                <fpage>249</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">18195088</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.morris.2007.1602s">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>SM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Arginine metabolism: boundaries of our knowledge.</article-title>
                <source>J Nutr</source>
                <volume>137</volume>
                <fpage>1602S</fpage>
                <lpage>9S</lpage>
                <pub-id pub-id-type="pmid">17513435</pub-id>
              </element-citation>
            </ref>
            <ref id="lpi.REF.br_er.2011.193">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Br&#x000f6;er</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palacin</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>The role of amino acid transporters in inherited and acquired diseases.</article-title>
                <source>Biochem J.</source>
                <year>2011</year>
                <volume>436</volume>
                <fpage>193</fpage>
                <lpage>211</lpage>
                <pub-id pub-id-type="pmid">21568940</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="lpi.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="lpi.Acknowledgments">
          <title>Acknowledgments</title>
          <p>MICINN (SAF 2009-12606-C02-02) and SGR01490 to VN</p>
        </sec>
        <sec id="lpi.Author_History">
          <title>Author History</title>
          <p>Simona Fecarotta, MD; Federico II University (2006-2011)Virginia Nunes, PhD (2011-present)Gianfranco Sebastio, MD (2006-present)Maria Pia Sperandeo, PhD; Federico Il University (2006-2011)</p>
        </sec>
        <sec id="lpi.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>13 October 2011 (cd) Revision: targeted mutation analysis for the c.895-2A&#x0003e;T founder mutation available clinically</p>
            </list-item>
            <list-item>
              <p>31 May 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 December 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>22 September 2006 (gs) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
